964 results about "Immunity response" patented technology

A federated distributed computational system enables secure biological data analysis and genomic medicine with enhanced oncological therapy capabilities. The system implements patient-specific tumor-on-a-chip analysis through microfluidic control systems and cellular heterogeneity preservation, while integrating fluorescence-enhanced diagnostics using CRISPR-LNP targeting and robotic surgical navigation. The architecture coordinates spatiotemporal analysis of gene therapy delivery through molecular imaging and immune response tracking, and implements bridge RNA integration with multi-target synchronization. Treatment selection is optimized through multi-criteria scoring and patient-specific simulation modeling. Each federated node contains a local processing unit for biological data analysis, privacy preservation protocols, and a hierarchical knowledge graph structure. The system implements cross-species genetic analysis, environmental response modeling, and multi-scale tensor-based data integration, enabling research institutions to collaborate on complex, large-scale biological analyses while maintaining strict data privacy controls.

The present invention covers imidazo pyrimidine compounds of general formula (I), in which R1, R2, R3, R4 and Z are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant KRAS signaling, as a sole agent or in combination with other active ingredients.

The invention discloses a recombinant herpes zoster vaccine as well as a preparation method and application thereof, and particularly relates to the technical field of biological medicines. The recombinant herpes zoster vaccine comprises a recombinant herpes zoster vaccine fusion protein purified product HN101 and a liposome mixture HA201, and the recombinant herpes zoster fusion protein gE-gD is constructed by recombining reconstructed gE protein and reconstructed gD protein. The gE-gD recombinant herpes zoster fusion protein is obtained by reconstructing gE protein of varicella-herpes zoster virus and gD protein of HSV through a gene recombination technology and then recombining the gE protein and the gD protein. After the gE-gD recombinant herpes zoster fusion protein is combined with a liposome mixture HA201, stronger immune response can be induced, the antibody titer and cellular immunity are improved, the vaccine effect is enhanced, and meanwhile, the potential infection risk is avoided.

The present disclosure describes, in part, compositions and methods for safeguarding plant immunity to pathogens in response to environmental changes.

The present disclosure provides inter alia, molecules comprising a binding domain that binds specifically to a target antibody and at least one modified Fc domain. The present disclosure also provides methods and compositions that allow for selective depletion and / or neutralization of pathogenic antibodies.

The invention discloses a bovine rotavirus monoclonal antibody and a preparation method of a bovine rotavirus quantum dot immunochromatography test strip, and belongs to the technical field of bovine rotavirus monoclonal antibodies. According to the invention, a hybridoma cell strain BRV 3G9 is utilized, and a monoclonal antibody is prepared by adopting an ascites method; the BRV 3G9 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.46138. The BRV 3G9 is named as BRV 3G9. According to the present invention, the concentrated live virus immunized mouse is adopted to prepare the monoclonal antibody with strong immunoreaction, and the BRV quantum dot immunochromatography test strip is researched and developed on the basis of the monoclonal antibody, and has advantages of convenient use, high efficiency, high sensitivity, strong specificity and the like, and can achieve the rapid clinical differential diagnosis of calf diarrhea pathogens, the problem that grassroots veterinarians lack a clinical rapid detection technology is solved, the diagnosis and treatment level and the prevention and treatment effect are improved, and technical guarantee is provided for efficiently preventing and treating calf diarrhea and guaranteeing calf health.

The invention relates to the technical field of deep processing of cattle spleen, in particular to cattle spleen active polypeptide capable of enhancing immunity and a preparation method and a functional product thereof. The preparation method comprises the following steps: mincing cattle spleen, adding water, uniformly mixing, heating and curing; adding bacillus licheniformis alkaline protease to carry out hydrolysis for the first time; adding papain and bacillus subtilis flavourzyme into the first hydrolysate to carry out hydrolysis for the second time; and performing enzyme deactivation on the second hydrolysate, and sequentially performing fishy smell removal, decolorization, filtration, concentration and drying treatment to obtain the cattle spleen polypeptide. The cattle spleen polypeptide prepared by the invention can obviously enhance the immune response of a body and play a role in enhancing immunity, can be applied to a functional product for enhancing immunity as a functional factor, has the advantages of low equipment requirement, simple process, easiness in operation, high extraction efficiency and the like, is suitable for industrial production, and has a wide application prospect. The scheme of the invention has good application and economic prospects.

The present invention relates to a method for producing a canine atopic dermatitis animal model, a canine atopic dermatitis animal model produced thereby, and a use thereof. According to the present invention, a canine atopic dermatitis animal model is produced by skin stimulation on a dog through epicutaneous sensitization with ovalbumin at a concentration of 1 to 5 mg / ml once daily for 1 to 2 weeks and then with ovalbumin at a concentration of 1 to 5 mg / ml once daily for 2 to 8 weeks. The resulting animal model exhibits clinical symptoms of atopic dermatitis, changes in relevant factors such as increased expression levels of IgE and CCL17, and elevated expression levels of Th2-related cytokines IL-4, IL-31, and IL-13. Therefore, this invention enables the establishment of a standardized animal model for symptoms and Th2 immune responses appearing upon the onset of atopic dermatitis, and the model can be used in clinical studies for screening candidate agents for the prevention, alleviation, or treatment of atopic dermatitis.

The invention relates to application of cembratrienol in preparation of a medicine for preventing and / or treating psoriasis, and belongs to the technical field of biological medicine. The invention provides an application of cembratrienol in preparation of a medicine for preventing / or treating psoriasis. Researches find that cembratrienol can significantly inhibit secretion of inflammatory factors in a psoriasis-like cell model induced by M5; moreover, research finds that cembratrienol can significantly improve the skin lesion condition of an imiquimod-induced psoriasis mouse model, improve the weight loss degree of the psoriasis mouse model, relieve the pruritus condition of the psoriasis mouse model, improve the skin inflammation of the psoriasis mouse model, repair the skin barrier of the psoriasis mouse model, and improve the curative effect of the psoriasis mouse model. The body immune response of the psoriasis mouse model is reduced. Therefore, cembratrienol has a great application prospect in preparation of the medicine for preventing / treating psoriasis.

The invention discloses an intelligent monitoring and management method and system for postoperative care of tumor patients, and relates to the field of data analysis, and the main scheme is as follows: calculating a postoperative care state value # imgabs5 # according to a stability index # imgabs0 #, an equilibrium index # imgabs1 #, a wound inflammation immune response index # imgabs2 #, a pain tolerance and psychological toughness association index # imgabs3 # and a body temperature and immune response index # imgabs4 #; the problem that evaluation indexes are not comprehensive enough, are limited to basic vital sign data and meanwhile ignore relevance among different types of data, so that evaluation accuracy is reduced is solved, the body state of the user is judged according to the nursing state value # imgabs6 # and the nursing state threshold set, the body state of the patient can be accurately judged, and the evaluation accuracy is improved. And the efficiency and the pertinence of nursing work can be improved.

The present invention discloses a strain of Lactobacillus paracasei that simultaneously activates immune regulation and antioxidant pathways to alleviate vaginitis, belonging to the field of microbial technology. The present invention screened and obtained a strain of Lactobacillus paracasei CCFM1316, which has the effect of repairing related symptoms such as immune disorders and oxidative damage caused by vaginitis, specifically embodied in: reducing cellular NF-κB mRNA expression and cell supernatant IL-1β content, improving mouse vaginal immune response, enhancing mouse vaginal antioxidant capacity, improving mouse vaginal pathological manifestations and reducing pathogenic bacteria load. It reduces the mouse vaginal Gardnerella load and improves mouse vaginal pathological manifestations; therefore, Lactobacillus paracasei CCFM1316 has great application prospects in products that improve and repair immune disorders and oxidative damage problems caused by vaginitis.

The invention discloses a sorghum aphid MsCYP1 gene as well as an encoding protein, dsRNA (double-stranded ribonucleic acid) and application thereof, and aims to solve the technical problem that a key gene is lacked when an RNA (ribonucleic acid) interference technology is used for biological prevention and control of sorghum aphids at present. According to the application, the sorghum aphid protein MsCYP1 capable of being secreted into sorghum cells is screened, and the protein and the coding gene thereof can inhibit the content of hydrogen peroxide in sorghum and the immune response of the sorghum. Meanwhile, according to the cDNA sequence of the MsCYP1 gene of the sorghum aphid, dsRNA for the gene is designed, the dsRNA is introduced into the body of the sorghum aphid in an artificial feeding mode, it is found that the dsRNA can remarkably inhibit the MsCYP1 gene of the sorghum aphid, then the honeydew secretion amount and the reproduction rate of the sorghum aphid are affected, the MsCYP1 gene can serve as an RNAi target gene to be used for aphid prevention and control, pesticide use is reduced, and the application prospect is good. The ecological balance is maintained.

The invention belongs to the field of molecular biology, and particularly relates to application of OsDOF3 protein or a coding gene thereof to improvement of rice broad-spectrum disease resistance and regulation of agronomic traits. According to the application, an OsDOF3 knockout mutant and an overexpression transgenic line are constructed under the background of susceptible rice, resistance phenotype analysis is performed by inoculating various pathogenic bacteria (including pyricularia oryzae, rhizoctonia solani and bacterial blight), and it is proved that OsDOF3 participates in regulation and control of an immunoreaction pathway of rice to fungal diseases (rice blast and sheath blight) and bacterial diseases (bacterial blight). Meanwhile, the application also finds that after a strong promoter ubi is adopted for driving, an overexpression material of the OsDOF3 is shorter than that of a wild plant, and the OsDOF3 influences normal growth and development of rice while stimulating plant immune response. The invention provides important gene resources and molecular theoretical basis for developing a new variety of broad-spectrum disease-resistant rice.

Treatment of damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) is provided by delivering specialized pulsed electric field (PEF) energy to target tissue areas in a specific dose so as to obtain a superior outcome. The PEF energy and delivery has been optimized to provide advanced treatment of target tissue areas, including destruction of undesired tissue and generation of improved inflammatory and immune responses. These various types of treatment are controlled by a variety of factors including the electrode geometry, the dose of PEF energy delivered, the time the energy is delivered over, and the waveform of the PEF energy itself. The PEF energy is delivered in the form a dose which is considered to be one application of the specialized energy. Each dose creates a lesion in the target tissue area.

The invention belongs to the technical field of biological medicines, and relates to application of Ackermann muciniphile or its external vesicles in preparation of a drug for treating schistosomiasis. The anti-infection immunity of a host is enhanced by adjusting intestinal flora balance (recovering diversity and composition) and improving immune response (adjusting macrophage, CD8 + T cell recruitment and Th1 / Th2 balance); meanwhile, the intestinal barrier function is improved, and pathogen invasion and inflammation are reduced; hepatic granuloma and hepatic fibrosis caused by schistosome infection are obviously relieved, and the liver function is improved; the key effect of the MIF gene in immunoregulation is disclosed, and a new direction is provided for schistosomiasis immunotherapy. Besides, the probiotics are high in treatment safety and free of obvious side effects, can be combined with chemotherapy to enhance the curative effect and reduce the side effects and drug resistance of chemical drugs, provides a lasting and comprehensive adjuvant therapy scheme for the schistosomiasis, and has important clinical application potential.

The invention provides a genetic transformation method and application of muskmelon. The genetic transformation method comprises the following steps: carrying out co-culture treatment on an infected muskmelon explant and agrobacterium engineering bacteria in a sugar-free culture medium, and the sugar-free culture medium does not contain soluble sugar. By using the method, the co-culture time can be prolonged to 7-9 days, the infection efficiency of agrobacterium tumefaciens can be remarkably improved, the growth of the agrobacterium tumefaciens can be slowed down, agrobacterium tumefaciens pollution in the bud induction process is avoided, meanwhile, the immunoreaction of explants in the co-culture process is reduced, and the genetic transformation efficiency is further improved. Compared with an existing melon genetic transformation method in which co-culture time lasts for 4 days by adopting a sugar-containing culture medium, the genetic transformation method provided by the invention adopts a sugar-free culture medium and the co-culture time is prolonged to 8 days, so that the melon transgenosis efficiency can be improved by 14 times or more. The invention also provides an application of the genetic transformation method in preparation of a melon genetic transformation product.

The invention provides an applicable population screening method and application of a glioma dry-like cell sensitized DC vaccine, peripheral blood of a patient before and after inoculation of the glioma dry-like cell sensitized DC vaccine is obtained, mononuclear cells are extracted, CD8 + T cells are respectively separated from the mononuclear cells through a magnetic bead sorting method, and the CD8 + T cells are separated from the mononuclear cells. The method comprises the following steps: uniformly inoculating CD8 < + > T cells into an ELISPOT cell culture plate coated with an IFN-gamma antibody for culture, respectively setting an experimental group and a positive control group for culture, adding A2B5 < + > glioma cell lysis buffer into the experimental group and adding phytohemagglutinin into the positive control group, and carrying out ELISPOT staining on the cultured cells to obtain the secretion amount of FN-gamma before and after treatment of a patient. According to the secretion amount of the FN-gamma, patients with specific immune response to the glioma dry-like cell sensitization DC vaccine are screened, so that the glioma dry-like cell sensitization DC vaccine is conveniently popularized and applied, and the immune mechanism of the glioma dry-like cell sensitization DC vaccine is researched.

The invention discloses preparation and application of dual-network hydrogel. The dual-network hydrogel comprises the following components: (Z1) a spinal cord acellular matrix network DSM formed by self-assembly of a spinal cord acellular matrix dSECM; and (Z2) a metal-polyphenol network MPN formed by coordination of metal ions and polyphenols; wherein the DSM and the MPN are cross-linked through hydrogen bonds to jointly form a double-network structure. DSM provides a microenvironment suitable for cell survival and growth for the dual-network hydrogel and induces stem cells to differentiate into neurons, and MPN provides the dual-network hydrogel with biological effects of inhibiting inflammation and accumulation of reactive oxygen species (ROS). The dual-network hydrogel has the advantages of the two components, the active component neurotrophic factor and the inhibitor loaded on the dual-network hydrogel can regulate and control immune response after SCI, improve neuroinflammation microenvironment and promote nerve repair, and a new strategy is provided for in-situ tissue repair of SCI.

The invention belongs to the technical field of agricultural biological control, and particularly relates to bacillus velezensis, a biological preparation and application of the bacillus velezensis in plant disease prevention and growth promotion. The bacillus velezensis is preserved in the China Center for Type Culture Collection, the preservation number of the bacillus velezensis is CCTCC NO: M 2025613, and the bacillus velezensis is classified and named as bacillus velezensis B54. Experiments show that the bacillus velezensis and the biological preparation thereof provided by the invention have broad-spectrum antagonistic activity, can effectively inhibit growth of pathogenic bacteria such as pythium spp and fusarium spp, induce plants to generate immune response, remarkably reduce the incidence rate of root rot and blight of the plants, can also generate plant growth stimulants, improve the development of plant root systems, improve the growth of the plant root systems and promote the growth of the plant root systems. The crop yield and quality are improved.

Systems and methods to assess immune receptor sequences can incorporate a language model to yield embedded representations and classification of immune status. Classification systems and method can include assessment of embedded immune receptor sequence representations that account for isotype or V(D)J gene segment selection. Systems and methods to assess immunity status can incorporate one or more classifiers to predict immune status.

A method for modulation of an immune response utilizing chiral nanoparticles. The chiral nanoparticles can be synthesized from nanoparticle seed precursors using circularly polarized light. The chirality of the NPs can be measured using chirality measures such as the Osipov-Pickup-Dunmeur index, the Hausdorff chirality measure and by using circular dichroism spectra, g-factor spectra, and maximum g-factor for a specific wavelength. In-vivo tests in mice showed a 2.27-fold enhancement of immune cell maturation and 1584-fold enhancement of IgG production by L-nanoparticles versus D-nanoparticles. Both the in-vivo and in-vitro immune responses monotonically depend on the chirality, measured as g-factors, of the nanoparticles, indicating that nanoscale chirality of the nanoparticles can be used to regulate immune cell maturation. Finally, L-nanoparticles demonstrated 1258-fold higher efficiency as adjuvants for the H9N2 influenza virus versus D-nanoparticles or Alum, opening a path to utilization of nanoscale chirality in immunology.

The invention discloses a preparation method of an antler-DCB (at) EVsABPCs bone graft material. The preparation method specifically comprises the following steps: step 1, preparing an Antler-DCB scaffold; step 2, preparing hydrogel containing 10% of HAMA and ABPCs-Evs (2, 2 '-(1, 2, 4-trimethyl-1, 3, 4- Step 3, mixing; step 4, taking Antler-DCB, and immersing the Antler-DCB into the HAMA hydrogel containing the ABPCs-EVs; and step 5, exposing to 405nm ultraviolet light for 30 seconds to obtain the bone graft material. The invention further discloses the antler-DCB (at) EVsABPCs bone graft material. According to the antler-DCB-coated EVsABPCs bone graft material and the preparation method thereof disclosed by the invention, the strong capability of adjusting osteogenesis, angiogenesis, neurogenesis and immune response is obtained, so that a potential therapeutic intervention measure is provided for treating serious bone defects.

Provided herein are Toll-like receptor 2 (TLR2) agonists for use in enhancing human immune response and / or as adjuvants in vaccines. The TLR2 agonists include thiophenes, imidazoles, or phenyl-containing compounds, which may be compounds of Formulae (I), (II), (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers of an immune response (e.g., innate and / or adaptive immune response), and are useful in treating and / or preventing a disease, as adjuvants in a vaccine for the disease. (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

Disclosed is a compound represented by the following structural formula (I): or a pharmaceutically acceptable salt thereof. The variables of structural formula (I) are described herein. The compound of the invention can be attached to chelating groups for radionuclide binding and are therefore suitable for radioimaging and / or radiotherapy applications, for example the disclosed compounds can be radiolabeled with a positron emitter such as 18F, 68Ga or 64Cu, and used for positron emission tomography (PET). Alternatively, the compounds can be radiolabeled with an alpha particle emitter such as 225 Ac, a beta particle emitter such as 67Cu or 177Lu, or an Auger electron emitter (e.g. 111In, 67Ga, 99mTc, 195mPt, 125I and 123I). The compounds can also be attached to a cytotoxic agent for targeted delivery of the cytotoxic agent to tumors, for example conjugated to gemcitabine or doxycycline, or a venom. Likewise, the compounds can be conjugated to compounds having physiological effects, such as TLR agonists to stimulate the immune response of a recipient.

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and / or compositions to the subject.

Provided herein are chimeric hemagglutinin (HA) polypeptides and uses thereof for inducing an immune response (e.g., an antibody response) against influenza virus. Also provided herein are methods of generating antibodies to the chimeric HA polypeptides in a subject.

The invention belongs to the technical field of biomedicine, and discloses a nano-particle for enhancing radioimmunotherapy effect through cascade reaction and application of the nano-particle, a preparation method of the nano-particle comprises the following steps: S1, synthesis of ZnO2; the preparation method comprises the following steps: dissolving ZnCl2 and PVP in absolute ethyl alcohol, adding ammonia water and H2O2, after the reaction is completed, collecting precipitates, washing, and dispersing the precipitates in absolute ethyl alcohol to prepare ZnO2; and S2, synthesis of ZnO2 (at) Cu: resuspending ZnO2 in water, sequentially adding ammonia water, a PAA solution, IPA, dopamine hydrochloride and a CuCl2 solution, stirring in a nitrogen atmosphere, centrifuging, washing with ethanol, and drying in vacuum to obtain the ZnO2 (at) Cu nano-particles, namely the nano-particles. According to the nanoparticles, the radiotherapy effect is enhanced through cascade reaction, copper death is induced, immune response is activated, effective treatment on tumors is achieved, and the problems of radiotherapy resistance and immunosuppressive tumor microenvironment are solved.

The invention relates to the field of veterinary vaccines, in particular to a porcine pseudorabies virus antigen, a porcine pseudorabies subunit vaccine as well as a preparation method and application of the porcine pseudorabies virus antigen and the porcine pseudorabies subunit vaccine. The porcine pseudorabies virus antigen is porcine pseudorabies virus gD protein, and the amino acid sequence of the porcine pseudorabies virus gD protein is as shown in SEQ ID NO: 1. The porcine pseudorabies subunit vaccine prepared from the porcine pseudorabies virus antigen is simple in preparation method, high in neutralizing antibody value, strong in antigen immunity, capable of effectively activating immune response of a body and capable of playing a good immune protection role on porcine pseudorabies.

The present invention provides methods and compositions for the stimulation of immune responses and for treating or preventing allergic disease and responses and inflammatory disease and responses. In particular, the present invention provides nanoemulsion compositions and methods of using the same for the induction of immune responses that prevent or treat allergic disease by reducing allergic response. Compositions and methods of the invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.

The present invention relates to a WKYMVm peptide analog comprising an amino acid sequence of Trp (W)-Lys (K)-Tyr (Y)-Met (M)-Val (V)-D-Met (m), in which at least one amino acid residue selected from the group consisting of Lys (K), Tyr (Y), and Met (M) in the amino acid sequence is substituted with a β3-amino acid residue or a peptoid residue, and a use thereof. The WKYMVm peptide analogs of the present invention has effects of increasing stability by increasing in vivo degradation half-life and of promoting activation of innate immune responses by neutrophils through activation of formyl peptide receptors, and thus can be effectively used in preventing or treating a disease that is be prevented or treated by formyl peptide receptors, especially an infectious disease or inflammatory disease.